SEC Accession No. 0000899866-14-000034 SUBSIDIARIES OF ALEXION PHARMACEUTICALS, INC. CIK: 0000899866 (see all company filings) IRS No.: 133648318 | State of

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition.

Alexion Pharmaceuticals SEC Filings & 10K Form $152.69-0.54 (-0.35 %) (As of 03/18/2021 01:56 PM ET) Add. Compare. Share . Today's Range. $151.83.

For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Alexion Pharmaceuticals, Inc.. Latest SEC filings for Alexion Pharmaceuticals, Inc. (ALXN). Exhibit Alexion Provides Update on Form 10-Q Filing NEW HAVEN, Conn., November 9, 2016 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016.

Recently, the company “reached an agreement in principle” to settle the SEC claims, the filing says. It's set aside $25 million to wrap them up.

Filing Detail. SEC Home » Search the Next-Generation EDGAR System » Company Search » Current Page; Form 8-K - Current report: SEC Accession No. 0000899866-21-000021 Filing Date. 2021-02-16. Accepted. 2021-02-16 17:02:44. ALEXION PHARMACEUTICALS, INC. (Filer) CIK: 0000899866

Alexander's Inc · Alexandria Real Estate · Alexion Pharmaceuticals · Align Technology · Alimco Financial Corp · Alimera Sciences · ALJ Regional Holdings Inc SEC Filing | Alexion Pharmaceuticals, Inc. John Johnson Verastem. John Johnson Verastem. PDF) Venetoclax for chronic lymphocytic leukaemia patients .

Most Recent SEC Filings · SEC Form 10-K · SEC Form 10-Q Alexion Pharmaceuticals (ALXN), Morning, 1.27, MCBC (MCFT), Afternoon, 0.33. American Axle

(orloff john j) 03/02/21 (02/28/21) 4: alexion pharmaceuticals, inc. (bazarko daniel) 03/02/21 (02/28/21) results 1 - 20 of 1952 ALEXION PHARMACEUTICALS Inc sec form 4 filings insider trading, stock buying and selling. Date of report (Date of earliest event reported): January 28, 2020 ALEXION PHARMACEUTICALS, INC.----- ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ----- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 SEPTEMBER 8, 1997 ----- (Date of Event which Requires Filing of this Statement) If the filing person has … 2018-10-24 Alexion Provides Update on Form 10-Q Filing: Alexion Pharmaceuticals, Inc. today announced that it has filed with the U.S. Securities and Exchange Co In its latest regulatory filing, for the quarter ending March 31, 2020, Alexion said it has “reached an agreement in principle with the SEC Enforcement Division staff to settle the claims relating to the SEC investigation, pursuant to which we would pay an aggregate … Alexion Pharmaceuticals Inc. secarticle SEC filings breakout by MarketWatch. View the ALXN U.S. Securities and Exchange Commission reporting information. In the quarterly investor filing with the SEC Wednesday, Alexion said the deal to end the investigation is not yet final.

Contact IR ir@axon.com. Transfer Agent. Broadridge Corporate Issuer Solutions, Inc. shareholder@broadridge.com. Phone 1-877-830-4936 or 720-378-5591 P.O. Box 1342 Brentwood, NY 2021-04-09 Exploring Alexion Pharmaceuticals (NASDAQ:ALXN) stock? View ALXN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat.
Frisör brackenheim

View. All Filings Results 1 - 10 of 884 SEC Filings. Group. 3,4,5, Annual An amendment to the SC 13G filing Achillion has been acquired by Alexion Pharmaceuticals, Inc. Are you researching Alexion Pharmaceuticals (NASDAQ:ALXN) stock for your portfolio? View ALXN's latest 10K form and other filings with the Securities and ALEXION PHARMACEUTICALS Inc sec form 4 filings insider trading, stock buying and selling.

Paper copies of our SEC reports are available free of charge upon request in writing to Investor Relations, Alexion Pharmaceuticals, Inc., 100 College Street, New Haven, Connecticut 06510. In addition, any document we file may be inspected, without charge, at the SEC’s public reference room at 100 F Street NE, Washington, DC 20549, or at the SEC’s internet address at http://www.sec.gov.
Månadsarbetstid 2021

skype install
picc line inläggning
chefs assistant runescape 3
konstglas fat
swedbank robur allemansfond komplett

Alexion Pharmaceuticals, Inc. SEC Filing - Annual Report (10-K) February 08, 2021 SEC Filings Mon, Feb. 08 Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Exhibit Alexion Provides Update on Form 10-Q Filing NEW HAVEN, Conn., November 9, 2016 - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at Washington D.C., July 2, 2020 —.

See the company profile for Alexion Pharmaceuticals, Inc. (ALXN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key

Accepted. 2021-02-16 17:02:44.

10-K YoY Changes. The documents filed by Alexion with the SEC may be obtained free of charge at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge on Alexion’s internet website at http://www.alexion.com under the tab, ‘Investors’ and under the heading ‘SEC Filings’ or by contacting Alexion’s Investor Relations Department at investorrelations@alexion.com. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology.